Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Change where you give your injection each time
Researched applications In the published preclinical and clinical literature the effects of Cagrilintide are documented in the following areas: Obesity (stand-alone) , Phase 2 data (Lau 2021, 10.8 % at 4.5 mg) Obesity + Semaglutide (CagriSema) , Phase 3 REDEFINE 1 (25.3 %) T2DM + obesity , Phase 3 REDEFINE 2 Cardiovascular prevention , Phase 3 REDEFINE 3 (n ~ 7000) MASLD/MASH , exploratory in Phase 2 Type 2 diabetes (monotherapy) , preclinical data Prediabetes , exploratory plans Science & studies 4.1 Key publications Lau D.C.W., Erichsen L., Francisco A.M., et al
Zhang Z, Tang J, Song J, Xie M, Liu Y, Dong Z, Liu X, Li X, Zhang M, Chen Y, Shi H, Zhong J
RoumJHBorokZMcElvaneyNGGrimesGJBokserADBuhlRet alGlutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis
Common dosing ranges from 600-1200 mg per dose, typically administered 1-3 times weekly for 4-8 weeks
Research Outcomes 2.7
US$ 20.05
US$ 24.77
US$ 28.17
US$ 26.47
US$ 22.15
